• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Moolec Science SA

    4/17/25 7:33:08 PM ET
    $MLEC
    Blank Checks
    Finance
    Get the next $MLEC alert in real time by email
    6-K 1 ea0237971-6k_moolec.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rules 13a-16 or 15d-16 under

    the Securities Exchange Act of 1934

     

    For the month of April 2025

     

    Commission File Number: 001-41586

     

    MOOLEC SCIENCE SA

    (Exact name of Registrant as Specified in Its Charter)

     

    17, Boulevard F. W. Raiffeisen

    L-2411 Luxembourg,

    Grand Duchy of Luxembourg

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒          Form 40-F ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Form 6-K is incorporated by reference into our registration statements on Form F-3 (Registration No. 333-283113) and Form S-8 (Registration No. 333-282263).

     

    The exhibits to this Form 6-K contain important information relating to the business combination and the contributed entities, including:

     

    ●information relating to the structure of the business combination, the Business Combination Agreement, the businesses and assets of each of Bioceres Group PLC, Nutrecon LLC and Gentle Technologies Corp and certain risk factors. See “Exhibit 99.1—Background of the Business Combination,” “Exhibit 99.1—The Business Combination Agreement,” “Exhibit 99.1—Business of the Contributed Entities” and “Exhibit 99.1—Risk Factors”);

     

    ●the unaudited proforma condensed combined consolidated financial information for the year ended June 30, 2024 and unaudited pro forma condensed combined consolidated financial information as of and for the six-month period ended December 31, 2024. See “Exhibit 99.1—Unaudited Pro Forma Condensed Combined Consolidated Financial Information”;

     

    ●the audited consolidated financial statements of Bioceres Group PLC June 30, 2024 and 2023 and for the years ended June 30, 2024, 2023 and 2022. See “Exhibit 99.3”;

     

    ●the unaudited interim consolidated financial statements of Bioceres Group PLC as of December 31, 2024 and for the six-month period ended December 31, 2024 and 2023. See “Exhibit 99.4”; and

     

    ●the annual report on Form 20-F of Bioceres Crop Solutions Corp. for the year ended June 30, 2024 filed with the SEC on October 30, 2024. See “Exhibit 99.5”; and

     

    ●the unaudited consolidated financial statements of Bioceres Crop Solutions Corp. as of and for the six-month period ended December 31, 2024. See “Exhibit 99.6.”

     

    On April 9, 2025, Bioceres Group PLC converted from a public limited company to a private limited company and changed its name to Bioceres Group Limited. Therefore, the exhibits hereto containing financial statements of Bioceres Group Limited for periods ended prior to April 9, 2025 refer to those financial statements as the financial statements of Bioceres Group PLC.

     

    On March 4, 2025, we received a letter from the staff of the United States Securities and Exchange Commission, which, pursuant to its authority under Rule 3-13 of Regulation S-K, granted us relief from the requirement to include in our registration statements the financial statements of Gentle Technologies Corp and Nutrecon LLC, as required by Rule 3-05 of Regulation S-X, along with related pro forma information.

     

    Unless otherwise stated, references contained in the exhibits hereto to “the Form 6-K” are references to this Form 6-K.

     

     

     

     

    Forward-Looking Statements

     

    This current report on Form 6-K contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of our or the contributed entities are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this current report on Form 6-K, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that we may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of our or the acquired businesses and other risks and uncertainties, including those included under the header “Risk Factors” in our Annual Report on Form 20-F filed with the SEC, as well as our other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

     

    1

     

     

    Exhibit List

     

    Exhibit No.   Description
    99.1   Disclosure Statement relating to the Business Combination
    99.2   Business Combination Agreement dated as of April 17, 2025
    99.3   Audited consolidated financial statements of Bioceres Group PLC as of June 30, 2024 and 2023 and for the years ended June 30, 2024, 2023 and 2022
    99.4   Unaudited interim consolidated financial statements of Bioceres Group PLC as of December 31, 2024 and for the six months ended December 31, 2024 and 2023
    99.5   Annual report on Form 20-F of Bioceres Crop Solutions Corp. for the year ended June 30, 2024
    99.6   Interim unaudited consolidated financial statements of Bioceres Crop Solutions Corp. as of December 31, 2024 and June 30, 2024 and for the six months ended December 31, 2024 and 2023
    99.7   Consent of Price Waterhouse & Co. S.R.L., independent registered public accounting firm, with respect to Bioceres Group PLC’s consolidated financial statements
    99.8   Consent of Price Waterhouse & Co. S.R.L., independent registered public accounting firm, with respect to Bioceres Crop Solutions Corp.’s consolidated financial statements

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        MOOLEC SCIENCE SA
      (Registrant)
         
    Dated: April 17, 2025 By: /s/ Gastón Paladini
      Name:  Gastón Paladini
      Title: Chief Executive Officer

     

     

    3

     
    Get the next $MLEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLEC

    DatePrice TargetRatingAnalyst
    9/27/2023$5.00Buy
    ROTH MKM
    More analyst ratings

    $MLEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

      LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pe

      10/16/24 6:00:00 AM ET
      $MLEC
      Blank Checks
      Finance
    • Moolec Science Presents Fiscal Year 2024 Annual Business Update

      LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

      10/2/24 6:00:00 AM ET
      $MLEC
      Blank Checks
      Finance
    • Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

      LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

      9/25/24 6:00:00 AM ET
      $MLEC
      Blank Checks
      Finance

    $MLEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Moolec Science with a new price target

      ROTH MKM initiated coverage of Moolec Science with a rating of Buy and set a new price target of $5.00

      9/27/23 7:44:02 AM ET
      $MLEC
      Blank Checks
      Finance

    $MLEC
    Financials

    Live finance-specific insights

    See more
    • Moolec Science Presents Fiscal Year 2024 Annual Business Update

      LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

      10/2/24 6:00:00 AM ET
      $MLEC
      Blank Checks
      Finance
    • Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

      LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

      9/25/24 6:00:00 AM ET
      $MLEC
      Blank Checks
      Finance
    • Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

      LUXEMBOURG / ACCESSWIRE / May 23, 2024 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Third Quarter Fiscal Year 2024 on Thursday, May 30, 2024, before the market opens. Moolec Logo Moolec Science Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Thursday, May 30, 2024, at 08:30 a.m. ET.The Conference Call will be accompanied by a presentation

      5/23/24 7:00:00 AM ET
      $MLEC
      Blank Checks
      Finance

    $MLEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Moolec Science SA

      SC 13D - Moolec Science SA (0001937737) (Subject)

      4/17/24 5:14:28 PM ET
      $MLEC
      Blank Checks
      Finance
    • SEC Form SC 13D/A filed by Moolec Science SA (Amendment)

      SC 13D/A - Moolec Science SA (0001937737) (Subject)

      4/10/24 9:39:03 PM ET
      $MLEC
      Blank Checks
      Finance

    $MLEC
    SEC Filings

    See more
    • SEC Form 6-K filed by Moolec Science SA

      6-K - Moolec Science SA (0001937737) (Filer)

      5/13/25 11:33:56 AM ET
      $MLEC
      Blank Checks
      Finance
    • SEC Form 6-K filed by Moolec Science SA

      6-K - Moolec Science SA (0001937737) (Filer)

      4/29/25 5:29:32 PM ET
      $MLEC
      Blank Checks
      Finance
    • SEC Form 6-K filed by Moolec Science SA

      6-K - Moolec Science SA (0001937737) (Filer)

      4/22/25 8:30:49 PM ET
      $MLEC
      Blank Checks
      Finance